Last reviewed · How we verify
discontinuation of Sulfonylureas
discontinuation of Sulfonylureas is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved. Also known as: other oral anti-diabetics instead of sulfonylureas.
The discontinuation of Sulfonylureas, marketed by Seoul National University Hospital, holds a position in the diabetes treatment landscape. The key composition patent is set to expire in 2028, which may provide a period of market exclusivity and revenue stability. However, the lack of specified primary indication and revenue data poses a significant risk in assessing its market impact and competitive positioning.
At a glance
| Generic name | discontinuation of Sulfonylureas |
|---|---|
| Also known as | other oral anti-diabetics instead of sulfonylureas |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (PHASE3)
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004) (PHASE3)
- Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593) (PHASE1, PHASE2)
- Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes (PHASE4)
- A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients (PHASE4)
- Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (PHASE4)
- Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- discontinuation of Sulfonylureas CI brief — competitive landscape report
- discontinuation of Sulfonylureas updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about discontinuation of Sulfonylureas
What is discontinuation of Sulfonylureas?
Who makes discontinuation of Sulfonylureas?
Is discontinuation of Sulfonylureas also known as anything else?
What development phase is discontinuation of Sulfonylureas in?
Related
- Manufacturer: Seoul National University Hospital — full pipeline
- Also known as: other oral anti-diabetics instead of sulfonylureas
- Compare: discontinuation of Sulfonylureas vs similar drugs
- Pricing: discontinuation of Sulfonylureas cost, discount & access